NAP: Recovery (2007)
Citation:
Haub MD, Potteiger JA, Jacobsen DJ, Nau KL, Magee LA, Comeau MJ. Glycogen replenishment and repeated maximal effort exercise: effect of liquid carbohydrate. Int J Sport Nutr. 1999 Dec; 9 (4): 406-415.
PubMed ID: 10660871Study Design:
Randomized Controlled Trial
Class:
A - Click here for explanation of classification scheme.
Quality Rating:

Research Purpose:
To determine the effects of CHO ingestion during 60 minutes of recovery from short-duration high-intensity exercise.
Inclusion Criteria:
Exercising for at least three days a week for three months prior to testing.
Exclusion Criteria:
Not stated.
Description of Study Protocol:
- Recruitment: Not stated.
- Design: Counter-balanced, randomized trial
- Three testing occasions
- Test One was to determine VO2peak and familiarize with the 100-kJ protocol
- In Tests Two and Three, participants performed a 100-kJ test, consumed one of the two treatment beverages, rested for 60 minutes and then completed a second 100-KJ test. Testing sessions were separated by six, but not more than eight days.
- Blinding used: Double-blind
- Intervention: 20% solution of 0.7g per kg body mass maltodextrin (Gatorade) or an equal volume of placebo (aspartame) matched for taste
- Statistical analysis
- Time to complete the 100-KJ test was compared between treatments using dependent T-tests
- Energy and CHO were compared using dependent T-tests.
Data Collection Summary:
Timing of Measurements
- Subjects were tested on three occasions
- Initial testing session to determine VO2peak and Testing Sessions Two and Three were treatment conditions.
Dependent Variables
- Time to complete the work (seconds)
- VO2max (L per minute)
- Muscle tissue was analyzed for glycogen concentration
- Blood samples were analyzed for lactate, hemoglobin and hematocrit
- Subjects abstained from exercise for 24 hours prior to all testing.
Independent Variables
- 20% solution of 0.7g per kg body mass maltodextrin (Gatorade) or an equal volume of placebo (aspartame) matched for taste
- Refrained from consuming caffeine or alcohol for 24 hours prior to testing
- Diet was self-recorded for 48 hours prior to first assigned treatment.
Control Variables
None stated.Description of Actual Data Sample:
- Initial N: Six males
- Attrition (final N): Six males
- Age (mean±SD): 25.0±4.6 years
- Ethnicity: Not stated.
- Other relevant demographics (means±SD): Weight, 73.5±5.6kg; height, 181.0±5.6cm; VO2peak, 50.8±6.0ml per kg per minute
- Location: Kansas.
Summary of Results:
Variables |
CHO |
Placebo |
Statistical Significance of Group Difference |
Time to complete work during Ride One (seconds) |
323.0±38.3 |
317.8±32.6 |
NS |
Time to complete work during Ride Two (seconds) |
330.0±33.3 |
338.0±25.5 |
P<0.05 |
Other Findings
- No significant difference for CHO groups between Rides One and Two, but a significant increase in run time was reported between Ride One and Ride Two for the placebo group
- There were no significant differences between treatments for total energy intake or carbohydrate consumption for the 48 hours prior to testing.
Author Conclusion:
In summary, the ingestion of carbohydrates following short-duration, high-intensity exercise does not significantly enhance glycogen resynthesis during the first hour post-exercise or affect subsequent short-duration, high-intensity exercise. However, carbohydrate ingestion during 60 minutes of recovery from short-duration, high-intensity exercise significantly alters circulating plasma glucose concentration and seems to minimize the significant performance decrement observed following a placebo solution.
Funding Source:
Industry: |
|
||
University/Hospital: | University of Kansas |
Reviewer Comments:
Recruitment methods, inclusion criteria and exclusion criteria were not well-defined.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | ??? | |
2. | Was the selection of study subjects/patients free from bias? | ??? | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | No | |
2.2. | Were criteria applied equally to all study groups? | ??? | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | ??? | |
3. | Were study groups comparable? | N/A | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | N/A | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | N/A | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | Yes | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | Yes | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | Yes | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
6.6. | Were extra or unplanned treatments described? | N/A | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | ??? | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | ??? | |
7.7. | Were the measurements conducted consistently across groups? | ??? | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | N/A | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | ??? | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | N/A | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | ??? | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | ??? | |